J&J targets rare maternal-fetal diseases: 'We're going for this. No one else has.'
Rubraca sheds positive light for PARP inhibitors in endometrial cancer
Acorda filed for bankruptcy, and Merz is eyeing its assets
Abbott's heart valve repair device gets US approval
*please scroll down for all the latest news*
